Leerink Partnrs Forecasts Atyr PHARMA Q2 Earnings

Atyr PHARMA INC (NASDAQ:ATYR) – Investment analysts at Leerink Partnrs issued their Q2 2025 EPS estimates for Atyr PHARMA in a note issued to investors on Wednesday, May 7th. Leerink Partnrs analyst F. Khurshid expects that the company will earn ($0.17) per share for the quarter. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Atyr PHARMA’s current full-year earnings is ($0.91) per share. Leerink Partnrs also issued estimates for Atyr PHARMA’s Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.55) EPS and FY2026 earnings at ($0.41) EPS.

A number of other equities analysts have also weighed in on ATYR. Leerink Partners began coverage on Atyr PHARMA in a research note on Tuesday, February 18th. They set an “outperform” rating and a $16.00 price objective on the stock. HC Wainwright reissued a “buy” rating and set a $35.00 price target on shares of Atyr PHARMA in a research report on Friday, March 14th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Atyr PHARMA presently has a consensus rating of “Buy” and an average price target of $18.60.

Atyr PHARMA Price Performance

ATYR stock opened at $3.31 on Monday. Atyr PHARMA has a 1 year low of $1.42 and a 1 year high of $4.66. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. The firm has a market capitalization of $294.60 million, a PE ratio of -3.52 and a beta of 0.79. The business has a 50 day simple moving average of $3.27 and a 200-day simple moving average of $3.40.

Atyr PHARMA (NASDAQ:ATYR) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.02.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ATYR. JPMorgan Chase & Co. raised its position in Atyr PHARMA by 52.0% in the third quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company’s stock valued at $55,000 after purchasing an additional 10,754 shares during the period. Kingswood Wealth Advisors LLC acquired a new stake in shares of Atyr PHARMA during the 4th quarter worth about $170,000. Alterna Wealth Management Inc. purchased a new stake in Atyr PHARMA in the 4th quarter valued at about $36,000. D.A. Davidson & CO. purchased a new stake in Atyr PHARMA in the 4th quarter valued at about $141,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in Atyr PHARMA in the fourth quarter valued at about $144,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.